Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 5/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.50 |
| ▸ | ACACB | O00763 | 4/20 | 0.49 |
| ▸ | ACACA | Q13085 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23097299 | 0.93 | HDAC3 (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4518944 | 0.91 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20362435 | 0.82 | KMT2A (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17276694 | 0.81 | HDAC3 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17276728 | 0.80 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20362434 | 0.79 | KDM4E (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23097314 | 0.79 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL18730485 | 0.79 | SLC5A7 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2128579 | 0.79 | HDAC3 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2128570 | 0.79 | HDAC3 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145933-B1 | NAMPT INHIBITORS AND METHODS | GENZYME CORP (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20180312525-A1 | NAMPT Inhibitors for Cancer Therapy | GENZYME CORPORATION | 2018-11-01 | — | — | US | disclosed |
| US-10017523-B2 | NAMPT inhibitors and methods | GENZYME CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170107231-A1 | NAMPT Inhibitors and Methods | GENZYME CORPORATION | 2017-04-20 | — | — | US | disclosed |
| EP-3145933-A1 | NAMPT INHIBITORS AND METHODS | Genzyme Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2015179759-A1 | NAMPT INHIBITORS AND METHODS | GENZYME CORPORATION (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312525-A1 | NAMPT Inhibitors for Cancer Therapy | NAMPT, NME2, NQO1 | HDAC3 118/4885HDAC4 113/4885HDAC1 52/4885 |
| US-10017523-B2 | NAMPT inhibitors and methods | NAMPT, NAPRT, NME2 | HDAC3 234/4885HDAC4 319/4885HDAC1 134/4885 |
| US-20170107231-A1 | NAMPT Inhibitors and Methods | NAMPT, NAPRT, NME2 | HDAC3 234/4885HDAC4 319/4885HDAC1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.